ARTICLE | Company News

FDA approves Zytiga

April 29, 2011 1:24 AM UTC

FDA approved an NDA from Centocor Ortho Biotech Inc. for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in patients who have received prior docetaxel. Centocor is a subsidiary of Johnson & Johnson (NYSE:JNJ). ...